<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636076</url>
  </required_header>
  <id_info>
    <org_study_id>CQMF149F2202</org_study_id>
    <secondary_id>2012-001172-12</secondary_id>
    <nct_id>NCT01636076</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 µg/160 µg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 µg/500 µg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to
      salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with
      COPD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85</measure>
    <time_frame>12 weeks</time_frame>
    <description>Spirometry is conducted according to the global standard. Trough FEV1 is defined as the average of the 23 hour 10 minute and 23 hour 45 minute post dose FEV1 readings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 After First Dose and After 4 Weeks of Treatment</measure>
    <time_frame>Day 1 and Day 85</time_frame>
    <description>Spirometry is conducted according to the global standard. FEV1 is measured at pre-dose and post dose up to 1 hours on Day 1 and Day 28; 24 hours post-dose on Day 29 and 85. In a subset of approximately 60 patients, FEV1 is measured up to 20 hours postdose on Day 28 and Day 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for FEV1 (L), by Visit and Timepoint</measure>
    <time_frame>Day 1 through day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at Each Timepoint</measure>
    <time_frame>Day 1, Day 2, Day 28, Day , Day 29, Day 84, Day 85</time_frame>
    <description>Spirometry is conducted according to the global standard. FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC at Each Timepoint</measure>
    <time_frame>Day 1, Day 2, Day 28, Day , Day 29, Day 84, Day 85</time_frame>
    <description>Spirometry is conducted according to the global standard. FEV1/FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (L) on Day 1 Between-treatment Comparisons of AUC (5min - 4h)</measure>
    <time_frame>Day 1</time_frame>
    <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), Scheduled (not actual) time points are to be used. The standardized AUC(5 min - 4 h) for FEV1 will be summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC (5 Min-4 h),</measure>
    <time_frame>Day 1(Baseline), Day 28, Day 84</time_frame>
    <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min - 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for AUC (5 Min - 23 h 45 Min) for FEV1 (L) on Day 28 and Day 84 (Full Analysis Set, 24-h Profiling Subgroup)</measure>
    <time_frame>Day 28, Day 84</time_frame>
    <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min - 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Usage of Rescue Medication (Short Acting β2-agonist)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants record the number of puffs of rescue medication taken in the previous 12 hours each morning and evening throughout the 12 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Overall Change in Usage of Rescue Medication (Short Acting β2-agonist) .</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>This value represents the percent of days in the study where no rescue medication was needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures: SGRQ (St. George's Respiratory Questionnaire)</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>A Total and three component scores are calculated: Symptoms; Activity; Impacts. Each component of the questionnaire is scored separately:The score for each component is calculated separately by dividing the summed weights by the maximum possible weight for that component and expressing the result as a percentage: Score = 100 x Summed weights from all positive items in that component divided by Sum of weights for all items in that component The Total score is calculated in similar way: Score = 100 x Summed weights from all positive items in the questionnaire divided by Sum of weights for all items in the questionnaire Sum of maximum possible weights for each component and Total: Symptoms 566.2 Activity 982.9 Impacts 1652.8 Total (sum of maximum for all three components) 3201.9 The proportion of patients who achieve a clinically important improvement of at least 4 units in the total SGRQ will be analyzed. The higher the score the more symptoms of disease are present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the Proportion of Subjects With a Clinically Important Improvement of &gt;=1 Point in the TDI (Transitional Dyspnoea Index)Focal Score by Visit</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>A TDI focal score of ≥1 is considered to be a clinically important improvement from baseline. Analysis of the proportion of subjects with a clinically important improvement of &gt;=1 point in the TDI focal score, by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures: COPD Assessment Test</measure>
    <time_frame>Baseline, 4 and 12 weeks</time_frame>
    <description>It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Without Quantity Subscale</measure>
    <time_frame>Baseline, 4 and 12 weeks</time_frame>
    <description>Scoring the MOS Sleep Survey is a two-step process:• All items are scored so that a high score reflects more of the attribute implied by the scale name. Each item is converted to a 0 to 100 possible range so that the lowest and highest possible scores are set at 0 and 100, respectively. In this format, scores represent the achieved percentage of the total possible score. For example, a score of 50 represents 50% of the highest possible score.
• Second, items within each scale are averaged together to create the 7 scale scores. Scales with at least one item answered can be used to generate a scale score. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Scores represent the average for all items in the scale that the respondent answered. An additional measure is based on the average number of hours sleep each night during the past 4 weeks and are described in outcome measure 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Sleep Quantity Subscale</measure>
    <time_frame>Baseline, 4 and 12 weeks</time_frame>
    <description>The sleep quantity subscale,which refers to question 2 of the PRO: On average, how many hours did you sleep each night during the past 4 weeks. More hours of sleep indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics of COPD Exacerbations over12 Weeks as Defined by Chronic Pulmonary Disease Tool (EXACT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The EXACT is a 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in patients with COPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that were event free of a specified event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of COPD Exacerbations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (in Days) of COPD Exacerbations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Duration and number of the COPD exacerbation will be analyzed by the negative binomial regression model including treatment, country, smoking status, and COPD severity as factors and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With at Least One Exacerbation up to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that had an exacerbation up to week 12. Less exacerbations reflect a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in Days) to Permanent Study Discontinuation Due to COPD Exacerbation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients Who Permanently Discontinued Due to COPD Exacerbation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount (in Doses) of Systemic Corticosteroid Used to Treat COPD Exacerbation During the 12 Week Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total amount (in doses) of systemic corticosteroid used to treat COPD exacerbation will be summarized descriptively by treatment group per each systemic corticosteroid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cortisol Concentrations at Each Timepoint</measure>
    <time_frame>Day 1, Day 28, Day 84</time_frame>
    <description>Plasma cortisol to be measured in a subset of approximately 60 patients via central laboratory. Blood sample for Plasma cortisol is collected at pre-dose and post dose up to 4 hour on Day 1, up to 12 hours post-dose on Day 28 and Day 84, and 23 hour 35 minute on Day 2, Day 29, and Day 85, and at pre-dose 25 minute on Day 28, and Day 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Drug Concentrations (Pharmacokinetics) at Each Timepoint</measure>
    <time_frame>Day 1, 29, 84</time_frame>
    <description>Plasma indacaterol and mometasone furoate is to be measured in a subset of approximately 60 patients via central laboratory. Blood samples are collected at pre-dose on Day 1, 29, and 84; and post dose up to 4 hour on Day 1, up to 12 hours on Day 28 and 84. For sparse pharmacokinetic testing, blood samples will be collected at 23h 35 min post-dose following morning dose administration on Day 28 and 84, in all patients participating in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax</measure>
    <time_frame>Day 28, 84</time_frame>
    <description>Maximum observed plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter--Tmax</measure>
    <time_frame>Day 28, 84</time_frame>
    <description>Time to reach the maximum plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter--AUC0-t</measure>
    <time_frame>Day 28, 84</time_frame>
    <description>Area under the plasma concentration time curve from time zero to time &quot;t&quot; post-dose is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">629</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>QMF149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol xinafoate/fluticasone propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QMF149</intervention_name>
    <description>delivered via Concept1 device</description>
    <arm_group_label>QMF149</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>delivered via Accuhaler®</description>
    <arm_group_label>Salmeterol xinafoate/fluticasone propionate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to very severe COPD (GOLD 2 to GOLD 4) according to the 2011
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines

          -  Patients with a post-bronchodilator FEV1 &lt; 70% of the predicted normal, and a
             post-bronchodilator FEV1/FVC &lt; 0.70 at run-in (Visit 101).

          -  Current or ex-smokers who have a smoking history of at least 10 pack years (defined as
             the number of packs of 20 cigarettes smoked per day multiplied by number of years the
             patient smoked. e.g.10 pack years = 1 pack /day x 10 yrs, or ½ pack/day x 20 yrs). An
             ex-smoker may be defined as a subject who has not smoked for ≥ 6 months at screening.

        Exclusion Criteria:

          -  Patients who have had a COPD exacerbation that required treatment with antibiotics
             and/or oral corticosteroids and/or hospitalization in the 6 weeks prior to screening
             (Visit 1).

          -  Patients who develop a COPD exacerbation between screening (Visit 1) and treatment
             (Visit 201) will not be eligible but will be permitted to be re-screened after a
             minimum of 6 weeks after the resolution of the COPD exacerbation.

          -  Patients who have had a respiratory tract infection within 4 weeks prior to screening
             Visit 1.

          -  Patients who develop a respiratory tract infection between screening (Visit 1) and
             treatment (Visit 201) will not be eligible, but will be permitted to be re-screened 4
             weeks after the resolution of the respiratory tract infection.

          -  Patients requiring long term oxygen therapy prescribed for &gt;12 hours per day.

          -  Patients with, a) any history of asthma or, b) onset of respiratory symptoms prior to
             age 40 years.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Franston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halen</city>
        <zip>3545</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Russe</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1234</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pori</city>
        <zip>FIN-28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>FIN-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion Crete</city>
        <state>Crete</state>
        <zip>GR-71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens - GR</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Larissa</city>
        <zip>GR 41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balasagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Farkasgyepu</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kapuvár</city>
        <zip>9330</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pécs</city>
        <zip>7633</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siofok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sopron</city>
        <zip>H-9401</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szarvas</city>
        <zip>5540</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar-Sava</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taiping</city>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ilawa</city>
        <zip>14-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pila</city>
        <zip>64-920</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-434</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Constanta</city>
        <state>Jud. Constanta</state>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>50159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2057</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Umkomaas</city>
        <zip>4170</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>405 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>412 63</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmö</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taladkwan</city>
        <state>Nonthaburi</state>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nakhon Naiyok</city>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Turkey</country>
    <country>Vietnam</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <results_first_submitted>September 10, 2014</results_first_submitted>
  <results_first_submitted_qc>November 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2014</results_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>QMF149</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
        </group>
        <group group_id="P2">
          <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
          <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="316"/>
                <participants group_id="P2" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QMF149</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
        </group>
        <group group_id="B2">
          <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
          <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="316"/>
            <count group_id="B2" value="313"/>
            <count group_id="B3" value="629"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="7.74"/>
                    <measurement group_id="B2" value="64.1" spread="7.89"/>
                    <measurement group_id="B3" value="64.5" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85</title>
        <description>Spirometry is conducted according to the global standard. Trough FEV1 is defined as the average of the 23 hour 10 minute and 23 hour 45 minute post dose FEV1 readings.</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients were included in the Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85</title>
          <description>Spirometry is conducted according to the global standard. Trough FEV1 is defined as the average of the 23 hour 10 minute and 23 hour 45 minute post dose FEV1 readings.</description>
          <population>All randomized patients were included in the Full analysis set (FAS)</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full analysis set (n=291,282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.270" spread="0.0124"/>
                    <measurement group_id="O2" value="1.215" spread="0.0124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per protocol set (n=259,251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.277" spread="0.0136"/>
                    <measurement group_id="O2" value="1.228" spread="0.0137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 After First Dose and After 4 Weeks of Treatment</title>
        <description>Spirometry is conducted according to the global standard. FEV1 is measured at pre-dose and post dose up to 1 hours on Day 1 and Day 28; 24 hours post-dose on Day 29 and 85. In a subset of approximately 60 patients, FEV1 is measured up to 20 hours postdose on Day 28 and Day 84.</description>
        <time_frame>Day 1 and Day 85</time_frame>
        <population>All randomized patients were included in the Safety analysis set (SAF) and Full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 After First Dose and After 4 Weeks of Treatment</title>
          <description>Spirometry is conducted according to the global standard. FEV1 is measured at pre-dose and post dose up to 1 hours on Day 1 and Day 28; 24 hours post-dose on Day 29 and 85. In a subset of approximately 60 patients, FEV1 is measured up to 20 hours postdose on Day 28 and Day 84.</description>
          <population>All randomized patients were included in the Safety analysis set (SAF) and Full analysis set (FAS).</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Day 2 (n=286, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.147" spread="0.0237"/>
                    <measurement group_id="O2" value="1.167" spread="0.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=286, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.216" spread="0.0106"/>
                    <measurement group_id="O2" value="1.243" spread="0.0104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Day 29 (n=293, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.148" spread="0.0236"/>
                    <measurement group_id="O2" value="1.178" spread="0.0266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=293,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.277" spread="0.0119"/>
                    <measurement group_id="O2" value="1.247" spread="0.0119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 baseline (n=289,287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.144" spread="0.0240"/>
                    <measurement group_id="O2" value="1.187" spread="0.0267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=289,287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.269" spread="0.0139"/>
                    <measurement group_id="O2" value="1.208" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for FEV1 (L), by Visit and Timepoint</title>
        <time_frame>Day 1 through day 85</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for FEV1 (L), by Visit and Timepoint</title>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absolute Value Day 1/5min (n=290,298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.254" spread="0.0069"/>
                    <measurement group_id="O2" value="1.198" spread="0.0068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 1/30 min (n=294,306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.281" spread="0.0079"/>
                    <measurement group_id="O2" value="1.250" spread="0.0087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 1/60min (n=300,303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.281" spread="0.0087"/>
                    <measurement group_id="O2" value="1.256" spread="0.0087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 2/ 23 hr 10 min (n=288,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.213" spread="0.0108"/>
                    <measurement group_id="O2" value="1.239" spread="0.0107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 2/ 23 hr 45 min (n=297,305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.215" spread="0.0106"/>
                    <measurement group_id="O2" value="1.244" spread="0.0105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 28/ -50min (n=288,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.265" spread="0.0132"/>
                    <measurement group_id="O2" value="1.287" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 28/ -15min (n=292,290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.287" spread="0.0132"/>
                    <measurement group_id="O2" value="1.235" spread="0.0140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 28/ 5min (n=290,289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.329" spread="0.0113"/>
                    <measurement group_id="O2" value="1.268" spread="0.0113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 28/ 30min (n=293,290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.352" spread="0.0118"/>
                    <measurement group_id="O2" value="1.298" spread="0.0118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 28/ 60min (n=292,290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.353" spread="0.0123"/>
                    <measurement group_id="O2" value="1.298" spread="0.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 29/ 23 hr 10 min (n=285,292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.269" spread="0.0118"/>
                    <measurement group_id="O2" value="1.242" spread="0.0117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 29/ 23 hr 45 min (n=290,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.281" spread="0.0123"/>
                    <measurement group_id="O2" value="1.254" spread="0.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ -50 min (n=286,278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.259" spread="0.0140"/>
                    <measurement group_id="O2" value="1.195" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ -15 min (n=282,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.282" spread="0.0146"/>
                    <measurement group_id="O2" value="1.222" spread="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ 5 min (n=280,279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.336" spread="0.0128"/>
                    <measurement group_id="O2" value="1.243" spread="0.0128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ 30 min (n=286,280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.352" spread="0.0124"/>
                    <measurement group_id="O2" value="1.277" spread="0.0124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ 60 min (n=287,281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.351" spread="0.0128"/>
                    <measurement group_id="O2" value="1.283" spread="0.0128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ 23 hr 10 min (n=292,291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.264" spread="0.0125"/>
                    <measurement group_id="O2" value="1.212" spread="0.0125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Value Day 84/ 23 hr 45 min (n=291,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.273" spread="0.0125"/>
                    <measurement group_id="O2" value="1.221" spread="0.0126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at Each Timepoint</title>
        <description>Spirometry is conducted according to the global standard. FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.</description>
        <time_frame>Day 1, Day 2, Day 28, Day , Day 29, Day 84, Day 85</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at Each Timepoint</title>
          <description>Spirometry is conducted according to the global standard. FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=316,313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.460" spread="0.6969"/>
                    <measurement group_id="O2" value="2.481" spread="0.7209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/ 5 min (n=299,298) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179" spread="0.2165"/>
                    <measurement group_id="O2" value="0.060" spread="0.1404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/ 30 min (n=302,306) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.207" spread="0.2279"/>
                    <measurement group_id="O2" value="0.129" spread="0.1953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/ 60 min (n=308,303) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.222" spread="0.2472"/>
                    <measurement group_id="O2" value="0.152" spread="0.2287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/ 4 hr (n=302,297) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.217" spread="0.2847"/>
                    <measurement group_id="O2" value="0.183" spread="0.2611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2/ 23hr 10 min (n=297,296) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.089" spread="0.2518"/>
                    <measurement group_id="O2" value="0.092" spread="0.2896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2/ 23hr 45 min (n=307,306) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" spread="0.2583"/>
                    <measurement group_id="O2" value="0.092" spread="0.2815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / -50 min (n=295,296) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.2806"/>
                    <measurement group_id="O2" value="0.068" spread="0.2814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / -15 min (n=300,291) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.3090"/>
                    <measurement group_id="O2" value="0.072" spread="0.2892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 5 min (n=297,290) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" spread="0.3163"/>
                    <measurement group_id="O2" value="0.122" spread="0.3068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 30 min (n=301,291) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.263" spread="0.3169"/>
                    <measurement group_id="O2" value="0.168" spread="0.3166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 60 min (n=299,292) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.279" spread="0.3261"/>
                    <measurement group_id="O2" value="0.189" spread="0.3350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 / 23hr 10 min (n=293,293) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.2955"/>
                    <measurement group_id="O2" value="0.084" spread="0.2817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 /23hr 45 min (n=299,296) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" spread="0.3132"/>
                    <measurement group_id="O2" value="0.097" spread="0.2965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / -50min (n=295,279) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.125" spread="0.2979"/>
                    <measurement group_id="O2" value="0.144" spread="0.3570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 /-15 min (n=291,286) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.144" spread="0.3234"/>
                    <measurement group_id="O2" value="0.049" spread="0.3519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 5 min (n=288,290) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.229" spread="0.3370"/>
                    <measurement group_id="O2" value="0.076" spread="0.3729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 /30 min (n=295,281) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.255" spread="0.3344"/>
                    <measurement group_id="O2" value="0.120" spread="0.3537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 60 min (n=296,282) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.272" spread="0.3295"/>
                    <measurement group_id="O2" value="0.159" spread="0.3648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 10 min (n=302,292) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="0.3132"/>
                    <measurement group_id="O2" value="0.022" spread="0.3482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 / 23 hr 45 min (n=301,286) Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" spread="0.3206"/>
                    <measurement group_id="O2" value="0.035" spread="0.3620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1/FVC at Each Timepoint</title>
        <description>Spirometry is conducted according to the global standard. FEV1/FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.</description>
        <time_frame>Day 1, Day 2, Day 28, Day , Day 29, Day 84, Day 85</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1/FVC at Each Timepoint</title>
          <description>Spirometry is conducted according to the global standard. FEV1/FVC is measured at pre-dose and post dose up to 4 hour on Day 1, Day 28, and Day 84, at post dose 12 hour, 23 hour 10 minute and 23 hour 45 minutes on Day 2 and Day 29, and at pre-dose 50 min and 15 min on Day 2, Day 28, and Day 84.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>FEV1/ FVC (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=316, 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.786" spread="10.0306"/>
                    <measurement group_id="O2" value="46.859" spread="10.0392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 5 min (n=299, 298) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.488" spread="2.9633"/>
                    <measurement group_id="O2" value="0.047" spread="2.1366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 30 min (n=302,306) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.955" spread="3.0166"/>
                    <measurement group_id="O2" value="0.879" spread="2.7281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 60 min (n=308,303) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.112" spread="3.1413"/>
                    <measurement group_id="O2" value="1.182" spread="3.0612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 4 hr (n=302, 297) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" spread="3.3917"/>
                    <measurement group_id="O2" value="1.397" spread="3.2407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 Hr 10 min (n=297,296) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.503" spread="3.3450"/>
                    <measurement group_id="O2" value="1.042" spread="3.2074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 / 23 Hr 45 min (n=307,306) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.583" spread="3.4552"/>
                    <measurement group_id="O2" value="1.319" spread="3.1977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / -50 min (n=295,296) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.463" spread="3.7864"/>
                    <measurement group_id="O2" value="1.140" spread="3.8900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / -15 min (n=300,291) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.837" spread="3.9769"/>
                    <measurement group_id="O2" value="1.495" spread="3.7597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 5 min (n=297,290) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.951" spread="4.0512"/>
                    <measurement group_id="O2" value="1.581" spread="4.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 30 min (n=301,291) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.296" spread="4.4904"/>
                    <measurement group_id="O2" value="1.873" spread="4.2723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 60 min (n=299,292) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.525" spread="4.3228"/>
                    <measurement group_id="O2" value="2.060" spread="4.4398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 4 hr (n=44,45) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.034" spread="5.2622"/>
                    <measurement group_id="O2" value="2.322" spread="4.0257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 11hr 10 min (n=47,44) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.553" spread="4.0260"/>
                    <measurement group_id="O2" value="1.909" spread="3.9389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 11hr 45 min (n=43,42) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.791" spread="4.1708"/>
                    <measurement group_id="O2" value="2.476" spread="4.3978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 16 hr (n=40,41) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.250" spread="3.4006"/>
                    <measurement group_id="O2" value="2.305" spread="4.3111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 20 hr (n=43,44) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.535" spread="3.5379"/>
                    <measurement group_id="O2" value="2.250" spread="3.9935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 / 23 hr 10 min (n=293,293) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.771" spread="4.0730"/>
                    <measurement group_id="O2" value="1.319" spread="3.8200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 / 23 hr 45 min (n=299,296) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" spread="4.0562"/>
                    <measurement group_id="O2" value="1.566" spread="3.9704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / -50 min (n=295,279) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.449" spread="4.1145"/>
                    <measurement group_id="O2" value="1.068" spread="4.1776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / -15 min (n=291,286) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.155" spread="4.0673"/>
                    <measurement group_id="O2" value="1.584" spread="4.3278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 5 min (n=288,280) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.332" spread="4.1032"/>
                    <measurement group_id="O2" value="1.796" spread="4.2310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 30 min (n=295,281) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.420" spread="4.3561"/>
                    <measurement group_id="O2" value="2.062" spread="4.3941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 60 min (n=296,282) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.571" spread="4.4128"/>
                    <measurement group_id="O2" value="2.067" spread="4.3512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 4 hr (n=45,44) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.389" spread="3.7079"/>
                    <measurement group_id="O2" value="2.682" spread="4.3269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 11hr 10 min (n=45,43) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.944" spread="4.0833"/>
                    <measurement group_id="O2" value="2.105" spread="3.8754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 11 hr 45 min (n=39,39) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.538" spread="3.7895"/>
                    <measurement group_id="O2" value="2.295" spread="4.1147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 16 hr (n=41,39) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.415" spread="4.0588"/>
                    <measurement group_id="O2" value="1.962" spread="3.6981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 20 hr (n=44,43) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.364" spread="4.4315"/>
                    <measurement group_id="O2" value="1.837" spread="3.7713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 23 hr 10 min (n=302,292) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.856" spread="4.4315"/>
                    <measurement group_id="O2" value="1.414" spread="4.0356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 23 hr 45 min (n=301,286) change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.098" spread="4.3676"/>
                    <measurement group_id="O2" value="1.593" spread="4.2110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (L) on Day 1 Between-treatment Comparisons of AUC (5min – 4h)</title>
        <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), Scheduled (not actual) time points are to be used. The standardized AUC(5 min – 4 h) for FEV1 will be summarized by treatment.</description>
        <time_frame>Day 1</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (L) on Day 1 Between-treatment Comparisons of AUC (5min – 4h)</title>
          <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), Scheduled (not actual) time points are to be used. The standardized AUC(5 min – 4 h) for FEV1 will be summarized by treatment.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Liters * hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 baseline (n=303,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.142" spread="0.0233"/>
                    <measurement group_id="O2" value="1.169" spread="0.0259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 post (n=303,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.277" spread="0.0086"/>
                    <measurement group_id="O2" value="1.260" spread="0.0085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC (5 Min-4 h),</title>
        <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min – 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.</description>
        <time_frame>Day 1(Baseline), Day 28, Day 84</time_frame>
        <population>24 hr profiling subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC (5 Min-4 h),</title>
          <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min – 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.</description>
          <population>24 hr profiling subgroup</population>
          <units>Liters*hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 baseline (n=46,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.302" spread="0.0278"/>
                    <measurement group_id="O2" value="1.331" spread="0.0282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=45,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.410" spread="0.0353"/>
                    <measurement group_id="O2" value="1.355" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=44,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.387" spread="0.0401"/>
                    <measurement group_id="O2" value="1.372" spread="0.0401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for AUC (5 Min – 23 h 45 Min) for FEV1 (L) on Day 28 and Day 84 (Full Analysis Set, 24-h Profiling Subgroup)</title>
        <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min – 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.</description>
        <time_frame>Day 28, Day 84</time_frame>
        <population>Peak FEV1 was calculated for all subjects in the FAS at Day 1 (Visit 201) and was calculated for all subjects in the 24-h profiling subset of the FAS at Day 1 (Visit 201), Day 28 (Visit 203) and Day 84 (Visit 205).</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for AUC (5 Min – 23 h 45 Min) for FEV1 (L) on Day 28 and Day 84 (Full Analysis Set, 24-h Profiling Subgroup)</title>
          <description>Spirometry is conducted according to the global standard. FEV1 AUC (5 min-4 h), (5 min-24 h) is measured after the first dose on Day 1 and on Day 28 and Day 84 in a subset of approximately 60 patients. Scheduled (not actual) time points are to be used. The interpretation of FEV1 at time 0 is the baseline value at the randomization visit and the latest pre-dose value (-50 min or -15 min) at subsequent visits. The standardized AUC(5 min – 4 h) for FEV1 will be summarized by treatment. The same will be repeated for standardized AUC for FEV1 between 5 min and 24 hours post morning dose.</description>
          <population>Peak FEV1 was calculated for all subjects in the FAS at Day 1 (Visit 201) and was calculated for all subjects in the 24-h profiling subset of the FAS at Day 1 (Visit 201), Day 28 (Visit 203) and Day 84 (Visit 205).</population>
          <units>Liters*hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n=45,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.352" spread="0.0428"/>
                    <measurement group_id="O2" value="1.298" spread="0.0431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=47,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.317" spread="0.0454"/>
                    <measurement group_id="O2" value="1.303" spread="0.0459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Usage of Rescue Medication (Short Acting β2-agonist)</title>
        <description>Participants record the number of puffs of rescue medication taken in the previous 12 hours each morning and evening throughout the 12 week treatment period.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>The Usage of Rescue Medication (Short Acting β2-agonist)</title>
          <description>Participants record the number of puffs of rescue medication taken in the previous 12 hours each morning and evening throughout the 12 week treatment period.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daily Change Weeks 1-12 (n-281,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.064" spread="0.1615"/>
                    <measurement group_id="O2" value="-0.593" spread="0.1621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime Change Weeks 1-12 (n=276-272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.625" spread="0.1021"/>
                    <measurement group_id="O2" value="-0.300" spread="0.1026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime Change Weeks 1-12 (n=281,271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.452" spread="0.0748"/>
                    <measurement group_id="O2" value="-0.308" spread="0.0751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Overall Change in Usage of Rescue Medication (Short Acting β2-agonist) .</title>
        <description>This value represents the percent of days in the study where no rescue medication was needed.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>The Overall Change in Usage of Rescue Medication (Short Acting β2-agonist) .</title>
          <description>This value represents the percent of days in the study where no rescue medication was needed.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>% of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.796" spread="2.3845"/>
                    <measurement group_id="O2" value="2.538" spread="2.3980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome Measures: SGRQ (St. George’s Respiratory Questionnaire)</title>
        <description>A Total and three component scores are calculated: Symptoms; Activity; Impacts. Each component of the questionnaire is scored separately:The score for each component is calculated separately by dividing the summed weights by the maximum possible weight for that component and expressing the result as a percentage: Score = 100 x Summed weights from all positive items in that component divided by Sum of weights for all items in that component The Total score is calculated in similar way: Score = 100 x Summed weights from all positive items in the questionnaire divided by Sum of weights for all items in the questionnaire Sum of maximum possible weights for each component and Total: Symptoms 566.2 Activity 982.9 Impacts 1652.8 Total (sum of maximum for all three components) 3201.9 The proportion of patients who achieve a clinically important improvement of at least 4 units in the total SGRQ will be analyzed. The higher the score the more symptoms of disease are present.</description>
        <time_frame>4 and 12 weeks</time_frame>
        <population>Full analysis set : At baseline all subjects with a baseline value are included. At each post-baseline day, only subjects with a value at both baseline and the respective day are included. Baseline SGRQ was completed on Day 1 prior to first dose.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome Measures: SGRQ (St. George’s Respiratory Questionnaire)</title>
          <description>A Total and three component scores are calculated: Symptoms; Activity; Impacts. Each component of the questionnaire is scored separately:The score for each component is calculated separately by dividing the summed weights by the maximum possible weight for that component and expressing the result as a percentage: Score = 100 x Summed weights from all positive items in that component divided by Sum of weights for all items in that component The Total score is calculated in similar way: Score = 100 x Summed weights from all positive items in the questionnaire divided by Sum of weights for all items in the questionnaire Sum of maximum possible weights for each component and Total: Symptoms 566.2 Activity 982.9 Impacts 1652.8 Total (sum of maximum for all three components) 3201.9 The proportion of patients who achieve a clinically important improvement of at least 4 units in the total SGRQ will be analyzed. The higher the score the more symptoms of disease are present.</description>
          <population>Full analysis set : At baseline all subjects with a baseline value are included. At each post-baseline day, only subjects with a value at both baseline and the respective day are included. Baseline SGRQ was completed on Day 1 prior to first dose.</population>
          <units>Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=314, 308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.05" spread="18.515"/>
                    <measurement group_id="O2" value="42.28" spread="17.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Baseline (n=304,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.87" spread="18.392"/>
                    <measurement group_id="O2" value="42.47" spread="18.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Post (n=304,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.95" spread="18.527"/>
                    <measurement group_id="O2" value="42.18" spread="18.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Change (n=304,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="11.383"/>
                    <measurement group_id="O2" value="-0.29" spread="12.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 Baseline (n=297,284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.57" spread="18.322"/>
                    <measurement group_id="O2" value="42.03" spread="18.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 Post (n=297,284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.81" spread="19.057"/>
                    <measurement group_id="O2" value="41.01" spread="18.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 Change (n=297,284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="13.062"/>
                    <measurement group_id="O2" value="-1.02" spread="12.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of the Proportion of Subjects With a Clinically Important Improvement of &gt;=1 Point in the TDI (Transitional Dyspnoea Index)Focal Score by Visit</title>
        <description>A TDI focal score of ≥1 is considered to be a clinically important improvement from baseline. Analysis of the proportion of subjects with a clinically important improvement of &gt;=1 point in the TDI focal score, by visit</description>
        <time_frame>4 and 12 weeks</time_frame>
        <population>Full analysis set, All randomized patients. When data were missing or insufficient for any one of the domains a focal score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of the Proportion of Subjects With a Clinically Important Improvement of &gt;=1 Point in the TDI (Transitional Dyspnoea Index)Focal Score by Visit</title>
          <description>A TDI focal score of ≥1 is considered to be a clinically important improvement from baseline. Analysis of the proportion of subjects with a clinically important improvement of &gt;=1 point in the TDI focal score, by visit</description>
          <population>Full analysis set, All randomized patients. When data were missing or insufficient for any one of the domains a focal score could not be calculated.</population>
          <units>(%) showing clinical improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 Change from baseline (n=291,294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="0.1314" lower_limit="0.79" upper_limit="1.68"/>
                    <measurement group_id="O2" value="40.5" spread="0.1331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 Change from baseline (n=287,283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="0.1330" lower_limit="0.99" upper_limit="2.05"/>
                    <measurement group_id="O2" value="45.9" spread="0.1390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome Measures: COPD Assessment Test</title>
        <description>It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.</description>
        <time_frame>Baseline, 4 and 12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome Measures: COPD Assessment Test</title>
          <description>It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 311,308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="7.60"/>
                    <measurement group_id="O2" value="16.2" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 baseline (n=303,298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="7.58"/>
                    <measurement group_id="O2" value="16.2" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Post (n=303,298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="7.63"/>
                    <measurement group_id="O2" value="16.8" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Change (n=303,298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="5.56"/>
                    <measurement group_id="O2" value="0.6" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 Baseline (n=295,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="7.54"/>
                    <measurement group_id="O2" value="16.1" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 Post (n=295,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="7.56"/>
                    <measurement group_id="O2" value="16.3" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 change (n=295,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="5.77"/>
                    <measurement group_id="O2" value="0.2" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Without Quantity Subscale</title>
        <description>Scoring the MOS Sleep Survey is a two-step process:• All items are scored so that a high score reflects more of the attribute implied by the scale name. Each item is converted to a 0 to 100 possible range so that the lowest and highest possible scores are set at 0 and 100, respectively. In this format, scores represent the achieved percentage of the total possible score. For example, a score of 50 represents 50% of the highest possible score.
• Second, items within each scale are averaged together to create the 7 scale scores. Scales with at least one item answered can be used to generate a scale score. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Scores represent the average for all items in the scale that the respondent answered. An additional measure is based on the average number of hours sleep each night during the past 4 weeks and are described in outcome measure 15.</description>
        <time_frame>Baseline, 4 and 12 weeks</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Without Quantity Subscale</title>
          <description>Scoring the MOS Sleep Survey is a two-step process:• All items are scored so that a high score reflects more of the attribute implied by the scale name. Each item is converted to a 0 to 100 possible range so that the lowest and highest possible scores are set at 0 and 100, respectively. In this format, scores represent the achieved percentage of the total possible score. For example, a score of 50 represents 50% of the highest possible score.
• Second, items within each scale are averaged together to create the 7 scale scores. Scales with at least one item answered can be used to generate a scale score. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Scores represent the average for all items in the scale that the respondent answered. An additional measure is based on the average number of hours sleep each night during the past 4 weeks and are described in outcome measure 15.</description>
          <population>Full analysis set.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep disturbance Day 28 Baseline (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6833" spread="8.57069"/>
                    <measurement group_id="O2" value="49.7616" spread="8.49307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance Baseline (n=299,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6423" spread="8.50059"/>
                    <measurement group_id="O2" value="49.9292" spread="8.51330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance Day 28 post (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9323" spread="8.92540"/>
                    <measurement group_id="O2" value="50.0858" spread="8.77110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance Day 28 change (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2490" spread="5.67591"/>
                    <measurement group_id="O2" value="0.3242" spread="6.63156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance Day 84 Baseline (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7622" spread="8.61100"/>
                    <measurement group_id="O2" value="49.6634" spread="8.41228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance Day 84 Post (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7508" spread="9.22016"/>
                    <measurement group_id="O2" value="50.2380" spread="9.07204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep disturbance Day 84 Change (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9887" spread="6.52972"/>
                    <measurement group_id="O2" value="0.5745" spread="6.45362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Baseline (n=299,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8815" spread="9.32313"/>
                    <measurement group_id="O2" value="49.8895" spread="9.18885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Day 28 Baseline (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8234" spread="9.40239"/>
                    <measurement group_id="O2" value="49.7733" spread="9.23030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Day 28 Post (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3476" spread="9.37744"/>
                    <measurement group_id="O2" value="49.5067" spread="9.39012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Day 28 change(n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5241" spread="6.70023"/>
                    <measurement group_id="O2" value="-0.2667" spread="7.06825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Day 84 Baseline (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8414" spread="9.29113"/>
                    <measurement group_id="O2" value="49.6385" spread="9.19681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Day 84 post (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4591" spread="9.29113"/>
                    <measurement group_id="O2" value="49.6108" spread="9.51632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep snoring Day 84 change (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6177" spread="7.42456"/>
                    <measurement group_id="O2" value="-0.0277" spread="8.266668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath Baseline (n=302,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5221" spread="13.28329"/>
                    <measurement group_id="O2" value="45.4259" spread="11.51560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath D 28 Bseline(n=293,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6348" spread="13.15710"/>
                    <measurement group_id="O2" value="45.3292" spread="11.48556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath D 28 post (n=293,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8814" spread="11.85664"/>
                    <measurement group_id="O2" value="45.5774" spread="11.65379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath D 28 change (n=293,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2466" spread="12.21272"/>
                    <measurement group_id="O2" value="0.2481" spread="11.44262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath D 84 Bseline (n=287,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8645" spread="12.99605"/>
                    <measurement group_id="O2" value="45.3180" spread="11.37006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath D 84 post (n=287,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7676" spread="13.20151"/>
                    <measurement group_id="O2" value="45.7049" spread="11.84910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep shortness of breath D 84 change (n=287,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9031" spread="12.11351"/>
                    <measurement group_id="O2" value="0.3870" spread="10.97093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy baseline (n=300,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9999" spread="9.85865"/>
                    <measurement group_id="O2" value="54.9725" spread="9.41704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy baseline D 28 (n=291,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0531" spread="9.80609"/>
                    <measurement group_id="O2" value="55.0679" spread="9.30955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy Post D 28 (n=291,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2032" spread="10.04281"/>
                    <measurement group_id="O2" value="54.8296" spread="10.21011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy Change D 28 (n=291,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1501" spread="9.83920"/>
                    <measurement group_id="O2" value="-0.2383" spread="9.21250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy baseline D 84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2125" spread="9.81055"/>
                    <measurement group_id="O2" value="55.1084" spread="9.20723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy Post D 84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2467" spread="10.00283"/>
                    <measurement group_id="O2" value="54.5424" spread="9.96705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy change D 84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0342" spread="8.81793"/>
                    <measurement group_id="O2" value="-0.5659" spread="8.57800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence baseline (n=302,296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6646" spread="9.56376"/>
                    <measurement group_id="O2" value="49.1709" spread="9.56807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence baseline D28 (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8711" spread="9.48940"/>
                    <measurement group_id="O2" value="49.1092" spread="9.58808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence post D28 (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4429" spread="9.93046"/>
                    <measurement group_id="O2" value="48.6761" spread="10.17850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence change D28 (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5718" spread="7.91162"/>
                    <measurement group_id="O2" value="-0.4331" spread="8.67719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence baseline D84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7821" spread="9.53639"/>
                    <measurement group_id="O2" value="48.9335" spread="9.55603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence post D84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2568" spread="10.36223"/>
                    <measurement group_id="O2" value="49.0461" spread="9.54132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep somnolence change D84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4747" spread="8.11292"/>
                    <measurement group_id="O2" value="0.1126" spread="7.83662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Baseline (n=300,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4795" spread="9.72203"/>
                    <measurement group_id="O2" value="50.8382" spread="9.16082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Baseline D28 (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6034" spread="9.67464"/>
                    <measurement group_id="O2" value="50.7911" spread="9.13425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Post D28 (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4799" spread="9.86137"/>
                    <measurement group_id="O2" value="50.7836" spread="10.02742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Change D28 (n=290,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8764" spread="7.03960"/>
                    <measurement group_id="O2" value="-0.0074" spread="7.73909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Baseline D84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7327" spread="9.64776"/>
                    <measurement group_id="O2" value="50.6951" spread="9.09626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Post D84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3590" spread="10.16584"/>
                    <measurement group_id="O2" value="50.9888" spread="9.54642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 1 Change D84 (n=284,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6263" spread="7.22742"/>
                    <measurement group_id="O2" value="0.2938" spread="7.08082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 baseline (n=299,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4610" spread="9.14154"/>
                    <measurement group_id="O2" value="51.0701" spread="8.62899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 baseline D 28 (n=289,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5720" spread="9.15508"/>
                    <measurement group_id="O2" value="50.9923" spread="8.60656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 Post D 28 (n=289,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5578" spread="9.43365"/>
                    <measurement group_id="O2" value="51.0116" spread="9.33837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 Change D 28 (n=289,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9858" spread="6.00711"/>
                    <measurement group_id="O2" value="0.0193" spread="6.99119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 Baseline D 84 (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6880" spread="9.16092"/>
                    <measurement group_id="O2" value="50.8848" spread="8.58893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 Post D 84 (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4615" spread="9.79518"/>
                    <measurement group_id="O2" value="51.1511" spread="9.09673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Problems Index 2 Change D 84 (n=283,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7735" spread="6.66709"/>
                    <measurement group_id="O2" value="0.2663" spread="6.29393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Sleep Quantity Subscale</title>
        <description>The sleep quantity subscale,which refers to question 2 of the PRO: On average, how many hours did you sleep each night during the past 4 weeks. More hours of sleep indicate better outcome.</description>
        <time_frame>Baseline, 4 and 12 weeks</time_frame>
        <population>Full analysis set.Higher scores show better outcomes.Excepting the sleep quantity subscale,scoring the MOS requires two steps:(a) assigning a point value to each response and (b) summing the point values for all the items in a given subscale or index. Each subscale and index score is then converted to a T score with a mean of 50 and an SD of 10.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome Measures: Medical Outcome Study (MOS) Sleep Scale: Sleep Quantity Subscale</title>
          <description>The sleep quantity subscale,which refers to question 2 of the PRO: On average, how many hours did you sleep each night during the past 4 weeks. More hours of sleep indicate better outcome.</description>
          <population>Full analysis set.Higher scores show better outcomes.Excepting the sleep quantity subscale,scoring the MOS requires two steps:(a) assigning a point value to each response and (b) summing the point values for all the items in a given subscale or index. Each subscale and index score is then converted to a T score with a mean of 50 and an SD of 10.</population>
          <units>hours of sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep quantity Baseline (n=301,295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5565" spread="1.44169"/>
                    <measurement group_id="O2" value="6.6203" spread="1.34895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep quantity Baseline D28(n=292,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5702" spread="1.44879"/>
                    <measurement group_id="O2" value="6.6351" spread="1.35775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep quantity Post D28(n=292,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5717" spread="1.54708"/>
                    <measurement group_id="O2" value="6.6246" spread="1.46356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep quantity Change D28(n=292,285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0015" spread="1.07390"/>
                    <measurement group_id="O2" value="-0.0105" spread="1.10691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep quantity Baseline D84(n=285,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5456" spread="1.42402"/>
                    <measurement group_id="O2" value="6.6496" spread="1.34500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep quantity Post D84(n=285,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5561" spread="1.43780"/>
                    <measurement group_id="O2" value="6.6569" spread="1.37648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep quantity Change D84(n=285,274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0105" spread="1.12270"/>
                    <measurement group_id="O2" value="0.0073" spread="1.18906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics of COPD Exacerbations over12 Weeks as Defined by Chronic Pulmonary Disease Tool (EXACT)</title>
        <description>The EXACT is a 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in patients with COPD.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics of COPD Exacerbations over12 Weeks as Defined by Chronic Pulmonary Disease Tool (EXACT)</title>
          <description>The EXACT is a 14-item electronic questionnaire designed to detect the frequency, severity, and duration of exacerbations in patients with COPD.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>COPD exacerbation per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.49"/>
                    <measurement group_id="O2" value="0.3" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation</title>
        <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that were event free of a specified event.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation</title>
          <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that were event free of a specified event.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Percentage of participants event free</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild COPD exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="97.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate COPD exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="92.0" upper_limit="97.1"/>
                    <measurement group_id="O2" value="88.5" lower_limit="84.9" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe COPD exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="96.5" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.3" lower_limit="96.9" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate or Severe COPD exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="89.9" upper_limit="95.7"/>
                    <measurement group_id="O2" value="86.8" lower_limit="82.9" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any( mild, moderate,severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="89.2" upper_limit="95.2"/>
                    <measurement group_id="O2" value="85.8" lower_limit="81.9" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of COPD Exacerbations</title>
        <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of COPD Exacerbations</title>
          <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>COPD Exacerbations per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Model based estimates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.354" lower_limit="0.2210" upper_limit="0.5663"/>
                    <measurement group_id="O2" value="0.659" lower_limit="0.4523" upper_limit="0.9592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Actual rate exacerbations per year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39">not calculated</measurement>
                    <measurement group_id="O2" value="0.73">not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration (in Days) of COPD Exacerbations</title>
        <description>Duration and number of the COPD exacerbation will be analyzed by the negative binomial regression model including treatment, country, smoking status, and COPD severity as factors and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Duration (in Days) of COPD Exacerbations</title>
          <description>Duration and number of the COPD exacerbation will be analyzed by the negative binomial regression model including treatment, country, smoking status, and COPD severity as factors and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="6.59"/>
                    <measurement group_id="O2" value="2.0" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With at Least One Exacerbation up to Week 12</title>
        <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that had an exacerbation up to week 12. Less exacerbations reflect a better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least One Exacerbation up to Week 12</title>
          <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates. The reported measure will detail the percentage of participants that had an exacerbation up to week 12. Less exacerbations reflect a better outcome.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (in Days) to Permanent Study Discontinuation Due to COPD Exacerbation</title>
        <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time (in Days) to Permanent Study Discontinuation Due to COPD Exacerbation</title>
          <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">number of observations is too small to project time to event</measurement>
                    <measurement group_id="O2" value="NA">number of observations is too small to project time to event</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients Who Permanently Discontinued Due to COPD Exacerbation</title>
        <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Who Permanently Discontinued Due to COPD Exacerbation</title>
          <description>Time-to-event variables will be analyzed by the Kaplan-Meier estimates and the stratified Cox proportional hazard model by smoking status and COPD severity. The model will include treatment and country as factors, and FEV1 prior to inhalation and FEV1 15 min post inhalation of salbutamol/albuterol as covariates.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>Percentage participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount (in Doses) of Systemic Corticosteroid Used to Treat COPD Exacerbation During the 12 Week Treatment Period</title>
        <description>Total amount (in doses) of systemic corticosteroid used to treat COPD exacerbation will be summarized descriptively by treatment group per each systemic corticosteroid.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set consisting of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount (in Doses) of Systemic Corticosteroid Used to Treat COPD Exacerbation During the 12 Week Treatment Period</title>
          <description>Total amount (in doses) of systemic corticosteroid used to treat COPD exacerbation will be summarized descriptively by treatment group per each systemic corticosteroid.</description>
          <population>Full analysis set consisting of all randomized patients</population>
          <units>(Prednisolone dose equivalents) mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IM Hydrocortisone (mg) (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="0"/>
                    <measurement group_id="O2" value="NA">no participants in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV dexamethasone (mg) (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="4.00" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Hydrocortisone (mg) (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Hydrocortisone sodium succinate (mg) (n=2,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.00" spread="282.843"/>
                    <measurement group_id="O2" value="NA">no participants in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV methylprenisolone sodium succinate(mg)(n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250" spread="0"/>
                    <measurement group_id="O2" value="NA">no participants in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV methylprenisolone sodium succinate(ug)(n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="80" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV prednisolone (mg) (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="250" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Budesonide (mg) (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="20" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral methylprenisolone (mg) (n=7,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.57" spread="11.414"/>
                    <measurement group_id="O2" value="20.31" spread="9.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral prednisolone (mg) (n=8,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.38" spread="9.520"/>
                    <measurement group_id="O2" value="23.93" spread="13.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral prednisone (mg) (n=8,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.25" spread="11.260"/>
                    <measurement group_id="O2" value="25.31" spread="11.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral prednisone (ug) (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="10" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhalation budesonide (mL)(n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">no participants in this group</measurement>
                    <measurement group_id="O2" value="0.50" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cortisol Concentrations at Each Timepoint</title>
        <description>Plasma cortisol to be measured in a subset of approximately 60 patients via central laboratory. Blood sample for Plasma cortisol is collected at pre-dose and post dose up to 4 hour on Day 1, up to 12 hours post-dose on Day 28 and Day 84, and 23 hour 35 minute on Day 2, Day 29, and Day 85, and at pre-dose 25 minute on Day 28, and Day 84.</description>
        <time_frame>Day 1, Day 28, Day 84</time_frame>
        <population>Safety set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149</title>
            <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol Xinafoate/Fluticasone Propionate</title>
            <description>Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cortisol Concentrations at Each Timepoint</title>
          <description>Plasma cortisol to be measured in a subset of approximately 60 patients via central laboratory. Blood sample for Plasma cortisol is collected at pre-dose and post dose up to 4 hour on Day 1, up to 12 hours post-dose on Day 28 and Day 84, and 23 hour 35 minute on Day 2, Day 29, and Day 85, and at pre-dose 25 minute on Day 28, and Day 84.</description>
          <population>Safety set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
          <units>nmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=45,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.5" spread="149.56"/>
                    <measurement group_id="O2" value="300.2" spread="107.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 15 min (n=44,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.0" spread="151.96"/>
                    <measurement group_id="O2" value="247.1" spread="91.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1 hr (n=44,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.1" spread="144.90"/>
                    <measurement group_id="O2" value="223.0" spread="85.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/ 4 hr (n=44,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.6" spread="85.90"/>
                    <measurement group_id="O2" value="205.7" spread="68.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 /23 hr 35 min (n=38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295.9" spread="153.80"/>
                    <measurement group_id="O2" value="274.2" spread="115.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/-25min (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.1" spread="160.16"/>
                    <measurement group_id="O2" value="295.6" spread="98.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 15 min (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.0" spread="140.83"/>
                    <measurement group_id="O2" value="239.8" spread="90.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 1 hr (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.9" spread="134.26"/>
                    <measurement group_id="O2" value="211.9" spread="89.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 4hr (n=40,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.9" spread="89.07"/>
                    <measurement group_id="O2" value="203.6" spread="108.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 11hr 35 min (n=40,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.8" spread="71.71"/>
                    <measurement group_id="O2" value="124.1" spread="72.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/ 23 hr 35 min (n=33,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.6" spread="99.81"/>
                    <measurement group_id="O2" value="306.5" spread="119.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 /-25 min (n=41,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.4" spread="155.24"/>
                    <measurement group_id="O2" value="324.1" spread="104.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 15 min (n=40,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.1" spread="144.26"/>
                    <measurement group_id="O2" value="265.5" spread="103.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 60 min (n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.3" spread="158.88"/>
                    <measurement group_id="O2" value="236.3" spread="104.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 4 hr (n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.4" spread="136.22"/>
                    <measurement group_id="O2" value="224.2" spread="100.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 11 hr 35 min (n=41,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.0" spread="99.66"/>
                    <measurement group_id="O2" value="147.5" spread="108.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 23 hr 35 min (n=37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.9" spread="159.51"/>
                    <measurement group_id="O2" value="315.9" spread="104.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Drug Concentrations (Pharmacokinetics) at Each Timepoint</title>
        <description>Plasma indacaterol and mometasone furoate is to be measured in a subset of approximately 60 patients via central laboratory. Blood samples are collected at pre-dose on Day 1, 29, and 84; and post dose up to 4 hour on Day 1, up to 12 hours on Day 28 and 84. For sparse pharmacokinetic testing, blood samples will be collected at 23h 35 min post-dose following morning dose administration on Day 28 and 84, in all patients participating in this study.</description>
        <time_frame>Day 1, 29, 84</time_frame>
        <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 (Analyte Mometasone Furoate)</title>
            <description>Assay Analyte: MOMETASONE FUROATE, component of QMF 149 mixture</description>
          </group>
          <group group_id="O2">
            <title>QMF149 (Analyte Indacaterol Acetate)</title>
            <description>Assay Analyte: QAB149 (Indacaterol acetate), component of QMF 149 mixture</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Drug Concentrations (Pharmacokinetics) at Each Timepoint</title>
          <description>Plasma indacaterol and mometasone furoate is to be measured in a subset of approximately 60 patients via central laboratory. Blood samples are collected at pre-dose on Day 1, 29, and 84; and post dose up to 4 hour on Day 1, up to 12 hours on Day 28 and 84. For sparse pharmacokinetic testing, blood samples will be collected at 23h 35 min post-dose following morning dose administration on Day 28 and 84, in all patients participating in this study.</description>
          <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 time 0 (n=34,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="13.8"/>
                    <measurement group_id="O2" value="4.32" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 15 min (n=44,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="17.9"/>
                    <measurement group_id="O2" value="111" spread="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 / 1 hr (n=43,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="19.3"/>
                    <measurement group_id="O2" value="89.7" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1/ 4 hr (n=43,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="15.6"/>
                    <measurement group_id="O2" value="51.4" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 /23 hr 35 min (n=37, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="16.7"/>
                    <measurement group_id="O2" value="44.8" spread="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 0 time (n=41,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="18.0"/>
                    <measurement group_id="O2" value="82.0" spread="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 15 min (n= 42,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="31.6"/>
                    <measurement group_id="O2" value="213" spread="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 1 hr (n=41,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="35.0"/>
                    <measurement group_id="O2" value="194" spread="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 4hr (n=42,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="25.7"/>
                    <measurement group_id="O2" value="132" spread="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 / 11hr 35 min (n=41,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="12.6"/>
                    <measurement group_id="O2" value="86.6" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/ 23 hr 35 min (n=45,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="7.32"/>
                    <measurement group_id="O2" value="76.5" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 0 time (n=39,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="30.5"/>
                    <measurement group_id="O2" value="101" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 15 min (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" spread="41.4"/>
                    <measurement group_id="O2" value="255" spread="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 60 min (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="40.6"/>
                    <measurement group_id="O2" value="241" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 4 hr (n=40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" spread="26.4"/>
                    <measurement group_id="O2" value="161" spread="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/ 11 hr 35 min (n=39,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="21.2"/>
                    <measurement group_id="O2" value="115" spread="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 / 23 hr 35 min (n=44,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="17.8"/>
                    <measurement group_id="O2" value="98.7" spread="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Cmax</title>
        <description>Maximum observed plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
        <time_frame>Day 28, 84</time_frame>
        <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 Analyte: Mometasone Furoate</title>
            <description>Mometasone furoate as part of QMF149F</description>
          </group>
          <group group_id="O2">
            <title>QMF149 Analyte: Indacaterol Acetate</title>
            <description>QAB149: indacaterol acetate as a component of QMF149F</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Cmax</title>
          <description>Maximum observed plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
          <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n=36,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="24.9"/>
                    <measurement group_id="O2" value="215" spread="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=32,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="23.0"/>
                    <measurement group_id="O2" value="263" spread="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter--Tmax</title>
        <description>Time to reach the maximum plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
        <time_frame>Day 28, 84</time_frame>
        <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF 149 Anaylyte: Mometasone Furorate</title>
            <description>Mometasone furoate as a component of QMF149F</description>
          </group>
          <group group_id="O2">
            <title>QMF149 Analyte: Indacaterol Acetate</title>
            <description>QAB149: indacaterol acetate as a component of QMF149F</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter--Tmax</title>
          <description>Time to reach the maximum plasma concentration after drug administration is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
          <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
          <units>Hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (n= 36 ,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" spread="0.833" lower_limit="0.080" upper_limit="3.98"/>
                    <measurement group_id="O2" value="0.970" spread="0.662" lower_limit="0.230" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n= 32 ,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" spread="1.92" lower_limit="0.220" upper_limit="11.7"/>
                    <measurement group_id="O2" value="1.00" spread="1.92" lower_limit="0.220" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter--AUC0-t</title>
        <description>Area under the plasma concentration time curve from time zero to time “t” post-dose is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
        <time_frame>Day 28, 84</time_frame>
        <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
        <group_list>
          <group group_id="O1">
            <title>QMF149 Analyte Mometasone Furoate</title>
            <description>QMF149 Mometasone furoate analyte from mixture</description>
          </group>
          <group group_id="O2">
            <title>QMF149 Analyte QAB149</title>
            <description>QMF149 analyte QAB149 ( indacaterol acetate)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter--AUC0-t</title>
          <description>Area under the plasma concentration time curve from time zero to time “t” post-dose is to be measured in a subset of approximately 60 patients via central laboratory, and will be determined for indacaterol and MF following morning dosing on Days 28 and 84.</description>
          <population>Moderate PK set: A total of 97 (15.4%) patients were included in the 24 h profiling FAS, safety plasma cortisol profiling subgroup, sparse and moderate PK sets.</population>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 Days (n=35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653" spread="296"/>
                    <measurement group_id="O2" value="2400" spread="771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Days (n=31,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="693" spread="297"/>
                    <measurement group_id="O2" value="2760" spread="802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>QMF149</title>
          <description>QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device</description>
        </group>
        <group group_id="E2">
          <title>SALM/FLUT</title>
          <description>SALM/FLUT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>SPUTUM PURULENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELECTROCARDIOGRAM T WAVE INVERSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PLEURAL MESOTHELIOMA MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>TEMPORAL LOBE EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>TENSION HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="316"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

